Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?

Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.

    What Lies Ahead for Vice ETFs?

    Vice ETFs, which aim to profit from companies involved in alcohol, tobacco or gambling, are gathering steam.

      Is a Beat in Store for Alexion (ALXN) This Earnings Season?

      Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

        Sweta Killa headshot

        Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

        Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

          Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?

          Solid prospects in Global Industrial, Global Energy and Global Institutional segments are likely to drive Ecolab's (ECL) Q1 earnings.

            Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

            Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

              J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

              Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

                Roche Hemophilia Drug Gets Breakthrough Therapy Designation

                The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

                  The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

                  The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

                    5 Drug Stocks Poised to Surpass on Earnings This Quarter

                    The outlook for the upcoming first-quarter results looks bright.

                      J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

                      J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

                        Shire Sells Oncology Unit Ahead of Takeda's Potential Offer

                        Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.

                          Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

                          The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                            Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

                            Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).

                              J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?

                              The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                                FDA Prolongs Review Date for AbbVie Endometriosis Candidate

                                The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.

                                  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis

                                  The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.

                                    AbbVie's RA Candidate Meets Primary Endpoints in Phase III

                                    AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.

                                      Biogen Cracks the Case With AbbVie for Humira Biosimilar

                                      Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.

                                        Aeglea Initiates Lung Cancer Combination Study With Keytruda

                                        Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.

                                          The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                          The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                            Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus

                                            Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.

                                              AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome

                                              AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting

                                                Ryan McQueeney headshot

                                                Why Is AbbVie (ABBV) Stock Crashing Today?

                                                Shares of pharmaceutical behemoth AbbVie Inc. (ABBV) dropped more than 11% in early morning trading Thursday after the company???s Rova-T program reported disappointing mid-stage results.

                                                  J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit

                                                  J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.